of today. We for and our The joining everyone call busy the stage as advances several thank also transaction. clinical fiscal third discovery important includes new you conference This existing well as business afternoon and programs us and It Arrowhead. period later since mid, includes development made for quarter in programs. and programs partnerships incredibly our last a Good Vince. early, Thanks been from development programs. has stage
few As a are platform attention. critical where company, our there we of a focus importance areas
First, boundaries of we what possible push need better. platform to the our make and is always TRiM
of candidates, expand the efficiently this Second, future. rapidly early-stage growth in clinical new will with to we important an need as and the source pipeline be
through to treatment to And and need move to mid without gets bringing important non-dilutive and clinical of TRiM partnering we our that our to lastly, pipeline patients in need it reach fund new of later-stage the closer options. Third, adequate medicines our helps programs we studies, bring use to as expand value platform to our development. the internal maximize goal and selectively capital
we I well all areas. these think doing in are
to that take of last events examples briefly review the this. key moment some a are quarter in Let’s good
discovery completed drug pipeline, includes which For IND-enabling a them new toxicology programs nominated studies. very the on pulmonary our and now GLP candidates. we are clinical manufacturing studies and early-stage for stage, We as quarter. optimization and discovery had clinical They and work clinical of in productive two both product
about disease We but be these year. the later targets, we and gene have the will yet more in not programs disclosed talking
at first and of very The dose-dependent achieve Annual International to genes. dystrophy, show the Society deep, muscle target the delivery TRiM a our that or achieve of types promising and skeletal on durable Research preclinical delivery knockdown as FSHD, Congress. FSHD with data can patients functional platform muscle presented being data muscle-targeted also facioscapulohumeral ARO-DUXX, XXth developed for We treatment muscular program various
models. animal of measures relevant multiple improved ARO-DUXX addition, muscle In preclinical in FSHD-like phenotype
to downstream is expression knockdown as may Arrowhead lead of of or DUXX DUXX using specifically options muscle address believes of in targeting reverse patients. pathology FSHD, selective repair RNAi and and need improvement cause treatments for recognized no prevent and muscle cause therapeutic that FSHD in new that patients the so root currently function muscle the myotoxicity the There in are the disease. effective patients, As
been the pushing pulmonary We this have well clinic aggressively we with two as ARO-DUXX the nominated candidates new toward as year.
toxicology pushed industry year, to a X of so seen on of been this challenging, CTAs file into the all end year. securing have the CROs CTAs the for for in unfortunate, of we of slots the pandemic. but first We half scheduling of will the beginning IND-enabling be the by since bottleneck but more become them next That the studies at is timely expected has
as of We paroxysmal nocturnal against glomerulopathy complement CX. diseases have Overactivation mediated target. of is of previously recently I hemoglobinuria a to number early am a and vascular, effective is cascade be recently on shown candidate including as other many nephropathy that node to programs of announce and We number activation, injury inhibition complement ARO-CX continued a is other complement pleased work the and hematologic a all causative in pathways of involved safe and treatment and can nominated of undisclosed three including in hepatocyte-directed diseases. CX thought complement the conditions, of neurologic of the been CX conditions. renal, central including well both many it a complement the mediated classical, be as alternative complement other and CX and in lectin has IgA pathways Complement
positive from us humans. TRiM-enabled more for reducing inhibition ARO-HBV, translate well of ARO-ANGX, the We CX may for the non-clinical hepatocyte-directed could file substantially be in confidence from in of choice and of CX a data for an ARO-CX siRNA X have ARO-APOCX, ARO-AAT, modality strong capable We track ARO-LPA, programs ARO-HSD. we to that Clinical AROCX the months end levels a candidates, record data that expect including these year. the believe and by or CTA gives
To-date, of which of I at our the of clinical or early-stage least is as a first believe investigational study ARO-HIFX progressed at developed with renal for we X,XXX ccRCC. dose up and is enrolling treatment of some potential The patients. meaningful our We potentially first efficacy which cell in clear been signs being ARO-HSD. ARO-HIFX patient. data tumor-targeted currently target that XXX program ARO-HIFX, milligrams two two dose the well start milligrams weekly, has has showing doses now to generally tolerated quarter, dosing ARO-HIFX of also engagement to interim for cell weekly. patients and During signs one early with announced programs, positive carcinoma, will and clear a in cohorts is
samples and a X of patients be via X minus evaluated was protein protein that could to the demonstrated XX%. H-score of of Specifically, HIFXα tumor reductions assessed XX reduction in minus These minus those HIFXα with mean immunohistochemistry. from reductions XX% X% ranged X had H-scores.
these In stable had best subject think disease. a broadly. We and response a response population tumor-targeted had results addition, a ARO-HIFX heavily with partial approximately our one subjects for pre-treated are of tumor in X XX% and early platform shrinkage encouraging
and positive milligrams, ARO-HSD single healthy patients lower We at ARO-HSD with liver XX. dose X diseases, X treatment for reduced effect a of at milligrams, given data Congress. interim pharmacodynamic XX the XXX a in showed tolerated being XX. volunteers biopsy NASH quantitation. All limit patients measurements a NASH International as reduced below well other potential as developed such three were Liver milligrams with the given XXX strong in in by for EASL suspected suspected at Day was the also or milligram while HSDXXBXX presented XX% XXX patients’ as XX NASH milligrams two and patients dose X Days liver protein of measured XX% patients, by and Day AROHSD on XX was with the
reductions to believe that investigational from XX%. ALT protein ARO-HSD therapeutic a XX%, of demonstrate inhibition and with hepatic ranging XX% Importantly, from HSDXXBXX is showed the We expression. mean baseline to robust patients all mRNA of reduction showing first
two see to ALT of also ARO-HSD. are We doses just highly drop following significantly levels encouraged
as including for treatment to X studies potential populations. progress in ARO-APOCX potential addition give will a dyslipidemia. that milestones on studies give our Phase across the together each few the details programs, programs, robust dosing started developed believe being started target early-stage or a of recently but will activity patient in minutes, mixed will some one X each start Xb program. already important us pipeline, to and In on as for about Phase with have study. and pipeline. picture medicine developed cardiometabolic more studies, we being more studies Javier intend ARO-ANGX the the various also two initiate a We for mid hypertriglyceridemia a we pharmacologic achieved two for I treatment later-stage our We our
We us Phase to are identify dose X enable the and intervals intending move confidently multiple into dose optimal to studies. to
rare also ARO-AAT, important quarter known TAK-XXX, a cardiometabolic Takeda genetic programs, our associated in In last for alpha-X treatment addition with we multiple co-developed liver being as deficiency. antitrypsin for the the disease events had as to with
liver mutant positive was that the designed up level what identified data ARO-AAT liver and to generally improvements to the doing multiple of very alpha-X XX-week after removing us the give begin and liver Congress. Liver is do to as treatment is with a and the see liver of at deficiency. tolerated additional to mutant sustained led that AAT been community. measures reductions AAT Takeda protein These rapid progressive the the treatment antitrypsin intervening can the alpha-X received ARO-AAT chance demonstrated even presented our treatment. in well patients from liver with others in important interim that This of and has with process, the year suggests and drug late-stage substantial have biopsy Mutant of and protein. We it to EASL AAT including is in we in X First, we were physicians results fibrosis, healing these health, cause results responses disease disease. when International protein thrilled similar patients results at to partners in treating
study, various patients various ARO-AAT study, the biopsies X dosed SEQUOIA enrolled the the cohorts we Phase fully dose with and various also the levels in recently. XXXX durations. XX treatment being have paired We patient from Combined XXth receiving open-label approximately will with
Lastly, Fast granted FDA. were designation the Track designation by also from from for Commission. designation Therapy the ARO-AAT, was previously and Drug designation we Orphan and Orphan the U.S. granted Breakthrough FDA ARO-AAT European
goal of provide ways to potential Our designations ARO-AAT each these of to that. and achieve the important is expedite path development
this important path to quickly. bring to We regulatory authorities from drug patients the will work and best our with Takeda to partners identify
option of to to I selectively use and progress Now, maximize helps the to value fund on reach component on non-dilutive as company Janssen, towards that executed platform was development. an chronic capital have ARO-HBV the an recent end The to that the progress. is which This mentioned, internal XXXX, strategy and and with against made X technology business expand area with in a important of we’ve B a we moving of seen believe where platform for should programs. bring we key additional the infection, our hepatitis collaboration included partnering partnering,
option previous agreement exercise with up to brought treatment Therapeutics to It studies. and potential the a the we not with in field of to with the with Horizon capital. previously the quarter, to potential player to for Janssen’s and $XX its milestones we space first ARO-JNJX. commercial candidate Janssen programs, During is is million million enter existing intent an brought organization. a partnering range expertise therapeutic Arrowhead receive developed receive those the and undisclosed needed receive regulatory great responsible gout. a an license to development, treatment being will during commercialization. eligible quarter, notice the It also ARO-XDH, delivered clinical right further dominant in of a Horizon a from discovery-stage to the $XX need, exclusive is on an and upfront clinical to attractive net uncontrolled as for and global to technology in be This in for move area low product intended will our million its Horizon example announced an development a option disease, earned written payment unmet as in signals the collaboration understand people and Arrowhead received help a expanded had $XXX of wholly the Arrowhead sales. to mid-teens license This and forward Also, for and by fee clinical intent reach the exercise of path, royalties independently the gout commercial eligible that opportunity. worldwide non-dilutive in tremendous and
perfect made patients these of we the this we reasons, therapy all thought sense deal to partner look was for We Horizon need. working with ideal For closely forward the Horizon our both for as in potential and companies. new advance
a quarter was exciting of this lots heard, you’ve As with busy events.
invariably and line straight a in are progress there doesn’t surprises. development drug However,
an in Sometimes potential program update last investigators and ARO-ENaC study this from investigational can in rats that we contained dosing of expected inflammation. sometimes instructed these a additional paused enrollment any these than being preliminary more Because To the clinical further latter to such program, surprises lead to We cystic ongoing chronic ongoing as and local additional the study. study for receiving screening, ongoing primate new ARO-AAT study experienced toxicology of toxicology the chronic leaps candidate treatment be after unexpected unwelcome. lung we healing surprises preliminary faster voluntarily developed a rat forward, review, update, data our of our from liver quarter. pause of chronic ARO-ENaC pending signals as an toxicology the fibrosis and ARO-ENaC the in
the study. or any in tolerability concerning people in AROENaCXXXX enrolled seen not We have signals safety
the in We continue not the the yet toxicology we data know additional the on pause above keep conducting ARO-ENaC that we study findings. clinical of we we clinical that participate not our yet else, of all now. are back for However, internally, do to studies have studies so trials so from safety place from the patients extent nor will full do
in still and to investigating the Javier are when should months to I’d overview, We to are the this more gathering and over Dr. like Javier? stage. we are and update that Martin. now in intend coming an provide information call fully weeks know With able. we San We turn the
